Centessa Pharmaceuticals Limited (CNTA) News

Centessa Pharmaceuticals Limited (CNTA): $4.52

-0.08 (-1.74%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Filter CNTA News Items

CNTA News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

CNTA News Highlights

  • CNTA's 30 day story count now stands at 2.
  • Over the past 7 days, the trend for CNTA's stories per day has been choppy and unclear. It has oscillated between 1 and 1.

Latest CNTA News From Around the Web

Below are the latest news stories about Centessa Pharmaceuticals plc that investors may wish to consider to help them evaluate CNTA as an investment opportunity.

Centessa Pharmaceuticals Doses First Subject in Global Phase 3 ACTION Study of Lixivaptan in Autosomal Dominant Polycystic Kidney Disease

BOSTON and LONDON, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA) (the “Company”), together with its subsidiary Palladio Biosciences, Inc. (“Palladio”), today announced it has started dosing of the first subject in its pivotal Phase 3 clinical trial (“ACTION Study”) evaluating lixivaptan as a potential treatment for Autosomal Dominant Polycystic Kidney Disease (“ADPKD”). The trial is expected to enroll approximately 1,350 subjects across more than 200 sites in over

Yahoo | February 24, 2022

Top 10 Stock Picks of Srini Akkaraju and Michael Dybbs’ Samsara BioCapital

In this article, we discuss the top 10 stock picks of Srini Akkaraju and Michael Dybbs’ Samsara BioCapital. You can skip our detailed analysis of Akkaraju and Dybbs’ history, investment philosophy, and hedge fund performance, and go directly to the Top 5 Stock Picks of Srini Akkaraju and Michael Dybbs’ Samsara BioCapital. Dr. Srinivas Akkaraju […]

Yahoo | February 17, 2022

Do Institutions Own Centessa Pharmaceuticals Limited (NASDAQ:CNTA) Shares?

Every investor in Centessa Pharmaceuticals Limited ( NASDAQ:CNTA ) should be aware of the most powerful shareholder...

Yahoo | January 1, 2022

Checking In On Centessa Pharmaceuticals

No summary available.

Seeking Alpha | December 23, 2021

Centessa Pharmaceuticals (NASDAQ:CNTA) Shares Gap Up to $11.33

Centessa Pharmaceuticals Limited (NASDAQ:CNTA) gapped up prior to trading on Tuesday . The stock had previously closed at $11.33, but opened at $11.82. Centessa Pharmaceuticals shares last traded at $12.03, with a volume of 1,219 shares changing hands. Separately, Zacks Investment Research raised Centessa Pharmaceuticals from a “hold” rating to a “buy” rating and set […]

Transcript Daily | December 23, 2021

Centessa Pharmaceuticals (NASDAQ:CNTA) Rating Lowered to Hold at Zacks Investment Research

Centessa Pharmaceuticals (NASDAQ:CNTA) was downgraded by Zacks Investment Research from a buy rating to a hold rating in a report released on Thursday, Zacks.com reports. According to Zacks, Centessa Pharmaceuticals plc is a clinical-stage company employing its innovative asset-centric business model to discover, develop and ultimately deliver impactful medicines to patients. Centessa Pharmaceuticals plc is []

Dakota Financial News | December 23, 2021

Boxer Capital, Llc Buys Tyra Biosciences Inc, Tango Therapeutics Inc, Blueprint Medicines Corp, ...

Investment company Boxer Capital, Llc (Current Portfolio) buys Tyra Biosciences Inc, Tango Therapeutics Inc, Blueprint Medicines Corp, Fulcrum Therapeutics Inc, Turning Point Therapeutics Inc, sells Seagen Inc, Amarin Corp PLC, Therapeutics Acquisition Corp, , Agenus Inc during the 3-months ended 2021Q3, according to the most recent filings of the investment company, Boxer Capital, Llc.

Yahoo | December 21, 2021

Compagnie Lombard Odier SCmA Takes $46,000 Position in Centessa Pharmaceuticals Limited (NASDAQ:CNTA)

Compagnie Lombard Odier SCmA bought a new stake in Centessa Pharmaceuticals Limited (NASDAQ:CNTA) in the 3rd quarter, Holdings Channel.com reports. The fund bought 2,750 shares of the companys stock, valued at approximately $46,000. Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. JPMorgan Chase []

Transcript Daily | December 18, 2021

Centessa Pharmaceuticals (NASDAQ:CNTA) Sets New 12-Month Low at $10.32

Shares of Centessa Pharmaceuticals Limited (NASDAQ:CNTA) hit a new 52-week low on Wednesday . The company traded as low as $10.32 and last traded at $10.35, with a volume of 2183 shares trading hands. The stock had previously closed at $11.10. Separately, Zacks Investment Research downgraded Centessa Pharmaceuticals from a buy rating to a hold []

Transcript Daily | December 17, 2021

Centessa Pharmaceuticals (NASDAQ:CNTA) Trading 11% Higher

Centessa Pharmaceuticals Limited (NASDAQ:CNTA) shares traded up 11% on Friday . The company traded as high as $12.20 and last traded at $12.20. 4,497 shares traded hands during trading, a decline of 98% from the average session volume of 200,208 shares. The stock had previously closed at $10.99. Separately, Zacks Investment Research lowered shares of []

Dakota Financial News | December 17, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.4773 seconds.